Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

PHASE3UnknownINTERVENTIONAL
Timeline

Start Date

September 30, 2002

Conditions
Melanoma (Skin)Metastatic Cancer
Interventions
BIOLOGICAL

aldesleukin

DRUG

histamine dihydrochloride

Trial Locations (19)

10003

Beth Israel Medical Center, New York

10021

Memorial Sloan-Kettering Cancer Center, New York

10466

Comprehensive Cancer Center at Our Lady of Mercy Medical Center, The Bronx

33612

Moffitt Clinic at Tampa General Hospital, Tampa

40202

James Graham Brown Cancer Center at University of Louisville, Louisville

63131

Melanoma Center of St. Louis, Missouri Baptist Medical Center, St Louis

65203

Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia

68135

Klinische Kooperationseinheit fur Dermatoonkologie (DFKZ), Mannheim

80010

University of Colorado Cancer Center at University of Colorado Health Sciences Center, Aurora

90404

John Wayne Cancer Institute at Saint John's Health Center, Santa Monica

60637-1470

University of Chicago Cancer Research Center, Chicago

15213-3489

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh

T6G 1Z2

Cross Cancer Institute, Edmonton

G1R 2J6

Centre Hospitalier Universitaire de Quebec, Québec

D-12200

Charite - Universitaetsmedizin Berlin, Berlin

D-66421

Universitatsklinik - Saarland, Homburg/Saar

DOH-24105

Kiel Universitatshautklinik, Kiel

D-81675

Klinikum Rechts Der Isar/Technische Universitaet Muenchen, Munich

SW3 6JJ

Royal Marsden Hospital - Sutton, London

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Maxim Pharmaceuticals

INDUSTRY

NCT00039234 - Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver | Biotech Hunter | Biotech Hunter